Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model - Wikidata - awgldk - TriplyDB

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

http://www.wikidata.org/entity/Q33486125

about

GLP-1 and cardioprotection: from bench to bedside Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.Cardiovascular and hemodynamic effects of glucagon-like peptide-1.The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.The cardiovascular effects of GLP-1 receptor agonists.Cardiovascular biology of the incretin system.Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism.Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium.Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.Incretin-based therapies.The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury.Cardiovascular effects of incretin-based therapies.The effect of glucagon-like peptide 1 on cardiovascular risk.Potential cardiovascular effects of incretin-based therapies.Cardioprotective effects of incretin during ischaemia-reperfusion.The impact of current and novel anti-diabetic therapies on cardiovascular risk.GLP-1 receptor agonists: effects on cardiovascular risk reduction.Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction.Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs.[Cardiovascular effects of incretin-based therapies].

P2860

Q27024984-FDBC7141-9393-48E6-A93C-C3CFD28750B1 Q28740948-65FA777D-D18F-4009-B6ED-A3FAD7CBF7EA Q33785308-18A861B8-CB14-413C-9DC6-13079EA61575 Q33993725-5011E98A-61D8-4D80-AEF8-0100B3521AA9 Q35017639-80050442-004D-4250-8DD8-AFBF99E2DC5B Q36368998-1050378A-43DA-496C-8838-982F264CCDC7 Q36484283-1C8FD071-5FD4-4630-8732-D81600AE9AA6 Q36689230-47898809-8273-45CF-A85D-32A090A43158 Q36721264-349CF693-36D6-4DB4-9A56-E68BEA2EB86B Q37082698-262FD940-CBC3-4DAA-8DC8-8536CE0783A9 Q37825946-DEF6577E-9474-40FF-9426-1DFD2657B79C Q37894864-F48435BB-2D00-4747-94EF-FE7A6DE0AEEB Q37926558-7C30DC85-0CBE-48F7-B61A-E67CA6B9AFC0 Q37977336-1CC08FBB-E58D-43AE-8EEA-58319170F131 Q37980019-6FB738EC-9F27-481D-B5EA-2FA713DE629A Q37990619-84954CB7-8886-4615-8681-94A5E0C16167 Q38002006-CA2D10F0-D00D-4E60-99CB-6EE0090C2C01 Q38062033-1CFB3FEF-BF23-44B5-B9CE-966865C2F8AB Q38122396-4F95BED4-5E86-420F-8D04-4C3370A5FCA9 Q38218639-783BA904-AE09-41B5-B899-13F3433D69C9 Q38797077-F05ABA63-5966-40F3-8177-080201A37658 Q50886415-FAF937F4-2C8A-4AD2-A06D-E6AB3D809F6D Q54522495-0A636B92-91D8-407A-A838-98EA3F5D04A1

P2860

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

http://www.wikidata.org/entity/Q33486125

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Lack of cardioprotection from ...... ine ischemia reperfusion model

@ast

Lack of cardioprotection from ...... ine ischemia reperfusion model

@en

type

label

Lack of cardioprotection from ...... ine ischemia reperfusion model

@ast

Lack of cardioprotection from ...... ine ischemia reperfusion model

@en

prefLabel

Lack of cardioprotection from ...... ine ischemia reperfusion model

@ast

Lack of cardioprotection from ...... ine ischemia reperfusion model

@en

P1433

Q33486125-EF7A2A86-45F4-467E-A5B1-891EFC5D6996

P1476

Q33486125-4D4F1D51-1F91-420F-B311-08D1F117D181

P2093

Q33486125-2B6ECE77-64CE-4AD9-8E7C-DF22D24720EB

Q33486125-750C4FE3-D7EA-4121-B806-1411242C40B9

Q33486125-9591BC25-8DB6-4F6A-9717-666B697DB093

Q33486125-BE130574-04B8-4ED2-9FD8-8DB97B0799B9

Q33486125-C07FCE25-F8B7-4887-8C16-5F392C744A74

P2860

Q33486125-08B94F08-D603-486E-915D-97A3171E2221

Q33486125-2ECB32FB-04F9-484C-9FB2-38C59EC35AB9

Q33486125-33EA7D5B-3267-4176-8722-E3BF2F5B3785

Q33486125-56957E55-87AA-4F84-8130-DDC611B93AAE

Q33486125-5D644B69-943A-46DC-BEB0-17D9C9C4FD1E

Q33486125-62EE163F-566D-4582-9541-5DD91300B0BE

Q33486125-7876C08E-A51C-49FB-B39B-A8CEBECE3FB2

Q33486125-7F9B2EBF-BC0C-4C68-99FB-38965386772A

Q33486125-9F65A939-229E-4F0B-B69E-CE5C723A81E4

Q33486125-AA766642-F3A9-46FC-8EA2-CB0E0915EEEC

P2888

Q33486125-9D7DA5FB-A50C-4186-8DBF-3E5E9F7B389F

P304

Q33486125-7E502CEF-6392-4962-8569-2DF51332C2D0

P31

Q33486125-14647666-6C06-4936-BFAC-09FA7CBCF6C9

P356

Q33486125-1D709C95-5535-49D1-B3B2-44AC070250C4

P478

Q33486125-E1E1E296-8DF5-40BD-B9E8-2BA30C562DE6

P50

Q33486125-15CA34A0-E1DA-417F-897F-8C266CA10BF0

P577

Q33486125-65D1A372-2B5D-4E84-BB00-704F9C02700D

P5875

Q33486125-52244938-4FA9-401E-8CE6-ABD0694D138C

P6179

Q33486125-E3E78BA1-FF64-4B36-9B3C-7F9734AD6D27

P698

Q33486125-6B94D738-A558-4C34-B614-58BB6B61E512

P932

Q33486125-E597B3A7-7EE2-42CB-90E4-41751452DABF

P356

P1433

BMC Cardiovascular Disorders

P1476

Lack of cardioprotection from ...... ine ischemia reperfusion model

@en

P2093

Jens Kristensen

http://www.w3.org/2001/XMLSchema#string

Michael Maeng

http://www.w3.org/2001/XMLSchema#string

Peter Haubjerg Nielsen

http://www.w3.org/2001/XMLSchema#string

Torsten Toftegaard Nielsen

http://www.w3.org/2001/XMLSchema#string

Ulrik M Mortensen

http://www.w3.org/2001/XMLSchema#string

P2860

Ischemic preconditioning: from adenosine receptor to KATP channel.

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

Myocardial protection at a crossroads: the need for translation into clinical therapy.

GLP-1 and extra-islet effects.

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.

P2888

P304

31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2261-9-31

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26690903

http://www.w3.org/2001/XMLSchema#string

P6179

1046717468

http://www.w3.org/2001/XMLSchema#string

P698

19627582

http://www.w3.org/2001/XMLSchema#string

P932

2728095

http://www.w3.org/2001/XMLSchema#string